Literature DB >> 22046493

Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design.

Ziyan Yuan1, Eric A Kumar, Stephen J Campbell, Nicholas Y Palermo, Smitha Kizhake, J N Mark Glover, Amarnath Natarajan.   

Abstract

Breast cancer gene 1 carboxy terminus (BRCT) domains are found in a number of proteins that are important for DNA damage response (DDR). The BRCT domains bind phosphorylated proteins and these protein-protein interactions are essential for DDR and DNA repair. High affinity domain specific inhibitors are needed to facilitate the dissection of the protein-protein interactions in the DDR signaling. The BRCT domains of BRCA1 bind phosphorylated protein through a pSXXF consensus recognition motif. We identified a hydrophobic pocket at the P-1 position of the pSXXF binding site. Here we conducted a structure-guided synthesis of peptide analogs with hydrophobic functional groups at the P-1 position. Evaluation of these led to the identification of a peptide mimic 15 with a inhibitory constant (K(i)) of 40 nM for BRCT(BRCA1). Analysis of the TopBP1 and MDC1 BRCT domains suggests a similar approach is viable to design high affinity inhibitors.

Entities:  

Year:  2011        PMID: 22046493      PMCID: PMC3201719          DOI: 10.1021/ml200147a

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  37 in total

1.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand.

Authors:  Xinyi Huang
Journal:  J Biomol Screen       Date:  2003-02

Review 2.  Emerging classes of protein-protein interaction inhibitors and new tools for their development.

Authors:  Len Pagliaro; Jakob Felding; Karine Audouze; Søren Jensby Nielsen; Robert B Terry; Christian Krog-Jensen; Steven Butcher
Journal:  Curr Opin Chem Biol       Date:  2004-08       Impact factor: 8.822

Review 3.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  Molecular basis of BACH1/FANCJ recognition by TopBP1 in DNA replication checkpoint control.

Authors:  Charles Chung Yun Leung; Zihua Gong; Junjie Chen; J N Mark Glover
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

5.  Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design.

Authors:  G L Lokesh; B K Muralidhara; Surendra S Negi; Amarnath Natarajan
Journal:  J Am Chem Soc       Date:  2007-08-09       Impact factor: 15.419

6.  Making optimal use of empirical energy functions: force-field parameterization in crystal space.

Authors:  Elmar Krieger; Tom Darden; Sander B Nabuurs; Alexei Finkelstein; Gert Vriend
Journal:  Proteins       Date:  2004-12-01

7.  Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.

Authors:  R Scott Williams; J N Mark Glover
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

Review 8.  BRCA1 16 years later: nuclear import and export processes.

Authors:  Marilyn E Thompson
Journal:  FEBS J       Date:  2010-07-01       Impact factor: 5.542

9.  BRCT repeats as phosphopeptide-binding modules involved in protein targeting.

Authors:  Isaac A Manke; Drew M Lowery; Anhco Nguyen; Michael B Yaffe
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

Review 10.  The role of BRCA1 in the cellular response to chemotherapy.

Authors:  Richard D Kennedy; Jennifer E Quinn; Paul B Mullan; Patrick G Johnston; D Paul Harkin
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

View more
  11 in total

Review 1.  BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.

Authors:  Seth M Dever; E Railey White; Matthew C T Hartman; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

Review 2.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.

Authors:  Sandeep Rana; Elizabeth C Blowers; Amarnath Natarajan
Journal:  J Med Chem       Date:  2014-08-28       Impact factor: 7.446

3.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

4.  Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain.

Authors:  E Railey White; Luxin Sun; Zhong Ma; Jason M Beckta; Brittany A Danzig; David E Hacker; Melissa Huie; David C Williams; Ross A Edwards; Kristoffer Valerie; J N Mark Glover; Matthew C T Hartman
Journal:  ACS Chem Biol       Date:  2015-02-05       Impact factor: 5.100

5.  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Authors:  Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

6.  Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.

Authors:  Ziyan Yuan Pessetto; Ying Yan; Tadayoshi Bessho; Amarnath Natarajan
Journal:  Breast Cancer Res Treat       Date:  2012-05-06       Impact factor: 4.872

Review 7.  Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.

Authors:  Qian Wu; Harry Jubb; Tom L Blundell
Journal:  Prog Biophys Mol Biol       Date:  2015-02-17       Impact factor: 3.667

8.  The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides.

Authors:  Eric A Kumar; Qianyi Chen; Smitha Kizhake; Carol Kolar; Myungshim Kang; Chia-En A Chang; Gloria E O Borgstahl; Amarnath Natarajan
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design.

Authors:  Wanli You; Yu-Ming M Huang; Smitha Kizhake; Amarnath Natarajan; Chia-En A Chang
Journal:  PLoS Comput Biol       Date:  2016-08-25       Impact factor: 4.475

10.  Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling.

Authors:  Jayaprakash Periasamy; Vadiraj Kurdekar; Subbarao Jasti; Mamatha B Nijaguna; Sanjana Boggaram; Manjunath A Hurakadli; Dhruv Raina; Lokavya Meenakshi Kurup; Chetan Chintha; Kavyashree Manjunath; Aneesh Goyal; Gayathri Sadasivam; Kavitha Bharatham; Muralidhara Padigaru; Vijay Potluri; Ashok R Venkitaraman
Journal:  Cell Chem Biol       Date:  2018-03-29       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.